Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma

Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma

GSK-3β is a serine/threonine kinase implicated in tumorigenesis and chemotherapy resistance. GSK-3β blockade downregulates the NF-κB pathway, modulates immune cell PD-1 and tumor cell PD-L1 expression, and increases CD8 + T cell and NK cell function. We report a case of adult T-cell leukemia/lymphom...

Full description

Bibliographic Details
Main Authors: Andrew Hsu, Kelsey E. Huntington, Andre De Souza, Lanlan Zhou, Adam J. Olszewski, Nirav P. Makwana, Diana O. Treaba, Ludimila Cavalcante, Francis J. Giles, Howard Safran, Wafik S. El-Deiry, Benedito A. Carneiro
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Cancer Biology & Therapy
Subjects:
atll
gsk-3
gsk-3b
9-ing-41
glycogen synthase kinase 3
Online Access:http://dx.doi.org/10.1080/15384047.2022.2088984

Similar Items

Similar Items